Sales Reps Will Make Case For Ranexa In First-Line Angina
This article was originally published in The Pink Sheet Daily
Executive Summary
New label, which exceeded CV Therapeutics’ expectations, highlights reduction of hemoglobin A1c levels and arrhythmias.
You may also be interested in...
Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics
In a surprise move spurred by a desire to own a greater share of the promising angina drug Ranexa, Astellas announced Jan. 27 its hostile offer for partner CV Therapeutics in a cash deal worth roughly $1 billion
Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics
Japanese pharma tries to downplay appearance of hostile bid driven largely by interest in Ranexa.
Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics
Japanese pharma tries to downplay appearance of hostile bid driven largely by interest in Ranexa.